Presentation is loading. Please wait.

Presentation is loading. Please wait.

Data on the world drug situation: Gaps and opportunities Sandeep Chawla Director Division for Policy Analysis and Public Affairs, UNODC.

Similar presentations


Presentation on theme: "Data on the world drug situation: Gaps and opportunities Sandeep Chawla Director Division for Policy Analysis and Public Affairs, UNODC."— Presentation transcript:

1 Data on the world drug situation: Gaps and opportunities Sandeep Chawla Director Division for Policy Analysis and Public Affairs, UNODC

2 Outline Why collect and analyse data on the drug situation? Existing data and indicators of the world drug situation –Production –Seizures –Prices –Use Data availability –present gaps –opportunities moving forwards

3 Drug production

4 Opium and cocaine production: Methods developed, reasonable certainty Opium Cocaine

5 Wide range of potential cultivation areas Wide variety of cultivation practices Many different cultivation scales and intensities Different processing and products Global cannabis production: estimation remains a challenge Outdoor areas potentially suitable for cannabis cultivation

6 Global ATS production, : Great uncertainty, and need for critique and improvement

7 Drug seizures

8 Drug seizure data – average improvements in recording HOWEVER Africa and Oceania still lack capacity, and data quality remains an issue

9 Drug prices

10 UNODC prices data collection: opium and coca products Monthly farm-gate prices –coca leaf and derivatives (Bolivia, Colombia, Peru) –opium (Afghanistan, Myanmar) Monthly trader prices in production areas Export value estimation –opium (Afghanistan) Consumer prices and purities –collected through ARQ

11 Price data collection challenges Very limited and outdated data: –Wholesale level (country to country) –Street level prices (except in some high income countries) Purity –Poorly monitored and reported Value added along trafficking routes –Poorly understood

12 Drug use

13 Data incredibly limited: drug use prevalence estimates

14 Drug use data Very few objective data on drug use –Even fewer direct measures of trends in drug use Expert perceptions of trends –most common source, but unknown validity Improve reporting against the 2000 Lisbon consensus? –Drug use: general population, young people –High risk drug use: injecting, risk behaviours –Drug problems

15 Moving forward: Increasing data collection and consolidation

16 Data collection Build data collection capacity –Develop drug information systems in regions of need –Support studies of drug use prevalence –Encourage collaborative links between countries within regions Use a strategic focus to direct activities –Build the SMART programme –Development of a new programme to improve drug use data collection Maximise integration with other data collection –Other health surveys and studies –Other regional drug information systems

17 Methodological issues The ARQ and BRQ –Are they still fit for purpose? –Can we improve reporting processes and outcomes? Data are often unclear or inconsistent –How should UNODC deal with such data? –Are additional review processes warranted? How can regional and global estimates best be made? –Methods of data imputation –Logic behind extrapolation of estimates to other countries

18 Addressing uncertainty Explicitly acknowledge and estimate uncertainty Increased transparency, critique and consultation Shared approach to data collection and interpretation Better coordination and collaboration –With member states –With drug monitoring organisations –With other external partners and experts

19 Revising global data collection: March 2009 mandate CND meeting in Vienna –Debates about current data –Debates about future processes Political declaration re-stated the importance of data to inform evidence-based drug policy Resolution passed that tasked UNODC with: –revising the Annual Reports Questionnaire –Improving and streamlining integrated data collection at the global level

20 Review process being undertaken by UNODC: 1.UNODC Expert meeting in July 2009: Vienna, Austria 2.Recommendations made for revisions to both process and tools – for consideration in November 3.Intergovernmental Expert Group meeting in November 2009: Vienna, Austria 4.Revised ARQ process and questionnaire developed for consideration by CND 5.UNODC reporting back to CND in March 2010: consideration and ratification Revising global data collection: the coming year


Download ppt "Data on the world drug situation: Gaps and opportunities Sandeep Chawla Director Division for Policy Analysis and Public Affairs, UNODC."

Similar presentations


Ads by Google